Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 6 of 6 entries
View as:

A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

Phase: N/A Priority: Normal
NCT ID: NCT04996797 Org: User:
Start: 07/28/21 End: 06/30/26 Due: 06/30/27

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

Phase: N/A Priority: Normal
NCT ID: NCT05270668 Org: User:
Start: 03/29/22 End: 07/31/29 Due: 07/31/30

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

Phase: N/A Priority: Normal
NCT ID: NCT05354349 Org: User:
Start: 04/06/22 End: 08/31/22 Due: 08/31/23

A Study of PRA023 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04676178 Org: User:
Start: 12/15/20 End: 09/23/21 Due: 09/23/22

A Study of PRA052 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT05603182 Org: User:
Start: 11/07/22 End: 02/21/24 Due: 02/21/25

A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05013905 Org: User:
Start: 09/01/21 End: 01/30/26 Due: 01/30/27